David Paterson, Infectious Diseases Physician

The University of Queensland Centre for Clinical Research, Australia

Disclosure(s): AMR Action Fund: Board Member; Aurobac: Advisor/Consultant; bioMerieux: Grant/Research Support, Honoraria; CARB-X: Advisor/Consultant; Entasis: Expert Testimony; Menarini: Honoraria; Merck: Grant/Research Support; Pfizer: Advisor/Consultant, Grant/Research Support; Shionogi: Grant/Research Support, Honoraria

Poster(s):

• (P-157) Molecular epidemiology of carbapenemase genes among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) from the Philippines: implications for surveillance and treatment
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-1517) Assessing the novel combinations against Carbapenem resistant Acinetobacter baunmannii (CRAB): ceftazidime-avibactam and ampicillin-sulbactam
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT